Lucid Diagnostics Announces Peer-Reviewed Publication Of Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study Of EsoGuard Esophageal Precancer Testing
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics, a subsidiary of PAVmed, announced positive results from a National Cancer Institute-sponsored study on EsoGuard, a test for esophageal precancer. The study, published in the American Journal of Gastroenterology, showed EsoGuard's high sensitivity in detecting early precancer, particularly in short-segment cases. These results support Lucid's efforts to secure commercial and Medicare payer coverage for EsoGuard. The company plans to seek Medicare coverage based on this data, aiming to provide a noninvasive, efficient screening method for esophageal cancer prevention.
May 02, 2024 | 11:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lucid Diagnostics announced significant positive results from a study on EsoGuard, supporting its efforts for commercial and Medicare payer coverage. This could enhance Lucid's market position and financial outlook.
The positive outcome from the EsoGuard study directly impacts Lucid Diagnostics by potentially increasing its product's marketability and adoption, especially if Medicare coverage is achieved. This could lead to increased revenue and market share in the cancer diagnostics sector.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
PAVmed, as the majority owner of Lucid Diagnostics, stands to benefit from the positive study results of EsoGuard, potentially enhancing its investment value and overall financial health.
PAVmed's majority ownership in Lucid Diagnostics means that positive developments for Lucid, such as the promising EsoGuard study results, could positively influence PAVmed's financial performance and valuation, given the potential for increased revenue and market presence.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80